Making the most of hypomethylating agents in myelodysplastic syndrome.

@article{Bhatt2017MakingTM,
  title={Making the most of hypomethylating agents in myelodysplastic syndrome.},
  author={Geetika Bhatt and William Blum},
  journal={Current opinion in hematology},
  year={2017},
  volume={24 2},
  pages={79-88}
}
PURPOSE OF REVIEW Hypomethylating agents (HMA) are the preferred therapy for patients with higher risk myelodysplastic syndromes (MDS) and an alternative therapeutic strategy for older patients with acute myeloid leukemia. These agents have improved both survival and quality of life, but results overall remain poor. The purpose of this review is to… CONTINUE READING